Buchumschlag

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey

The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecolo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Riedel, Maximilian (VerfasserIn) , Herrmann, Helene (VerfasserIn) , Bartl, Thomas (VerfasserIn) , Rossner, Anna-Maria (VerfasserIn) , Tatzber, Anna (VerfasserIn) , Flethe, Chiara (VerfasserIn) , Zocholl, Dario (VerfasserIn) , Schmalfeldt, Barbara (VerfasserIn) , Sehouli, Jalid (VerfasserIn) , Pietzner, Klaus (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 29 January 2025
In: BMC cancer
Year: 2025, Jahrgang: 25, Pages: 170-1-170-9
ISSN:1471-2407
DOI:10.1186/s12885-025-13432-5
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13432-5
Volltext
Verfasserangaben:Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli and Klaus Pietzner
Beschreibung
Zusammenfassung:The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.
Beschreibung:Gesehen am 02.10.2025
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-025-13432-5

Ähnliche Einträge